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A detailed phenotypic analysis of immune cell
populations in the bronchoalveolar lavage fluid of
atopic asthmatics after segmental allergen
challenge
Jonathan S Boomer1, Amit D Parulekar1,2, Brenda M Patterson1, Huiqing Yin-Declue1, Christine M Deppong1,
Seth Crockford1, Nizar N Jarjour3, Mario Castro1 and Jonathan M Green1*
Abstract
Background: Atopic asthma is characterized by intermittent exacerbations triggered by exposure to allergen.
Exacerbations are characterized by an acute inflammatory reaction in the airways, with recruitment of both innate
and adaptive immune cells. These cell populations as well as soluble factors are critical for initiating and controlling
the inflammatory processes in allergic asthma. Detailed data on the numbers and types of cells recruited following
allergen challenge is lacking. In this paper we present an extensive phenotypic analysis of the inflammatory cell
infiltrate present in the bronchoalveolar lavage (BAL) fluid following bronchoscopically directed allergen challenge
in mild atopic asthmatics.
Methods: A re-analysis of pooled data obtained prior to intervention in our randomized, placebo controlled,
double blinded study (costimulation inhibition in asthma trial [CIA]) was performed. Twenty-four subjects
underwent bronchoscopically directed segmental allergen challenge followed by BAL collection 48 hours later. The
BAL fluid was analyzed by multi-color flow cytometry for immune cell populations and multi-plex ELISA for cytokine
detection.
Results: Allergen instillation induced pro-inflammatory cytokines (IL-6) and immune modulating cytokines (IL-2, IFN-
γ, and IL-10) along with an increase in lymphocytes and suppressor cells (Tregs and MDSC). Interestingly,
membrane expression of CD30 was identified on lymphocytes, especially Tregs, but not eosinophils. Soluble CD30
was also detected in the BAL fluid after allergen challenge in adult atopic asthmatics.
Conclusions: After segmental allergen challenge of adult atopic asthmatics, cell types associated with a pro-
inflammatory as well as an anti-inflammatory response are detected within the BAL fluid of the lung.
Keywords: T lymphocyte, CD30 expression, Segmental allergen challenge, Asthma
Background
Asthma is a complex immunological disease affecting ap-
proximately 8-10% of the population of the United States
[1-3]. The pathology of asthma includes pulmonary
inflammation, airway eosinophilia, mucus hypersecretion
and airway hyperreactivity (AHR), induced by specific and
nonspecific stimuli which lead to an inappropriate Th2
response [1-3]. T lymphocytes of a Th2 type secrete IL-3,
IL-4, IL-5, IL-9, and IL-13 [1-3], cytokines which play im-
portant roles in Th2 lymphocyte survival, B cell isotype
switching to IgE and mast cell, basophil and eosinophil
differentiation and survival [1-4]. This complex inflamma-
tory cascade is controlled by soluble factors as well as in-
teractions between cell types involving surface receptors
such as CD80/86 on dendritic cells (DC) and CD28/
CTLA-4 on T cells [5-9], ultimately resulting in the
asthma phenotype [1-3].
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Although inflammation is critical to the pathogenesis
of asthma, the exact cell types present in the lung and
their differentiation state remain not well defined. In this
report, we characterized the immune cell populations
and cytokines present within the lungs of mild atopic
asthmatics that underwent bronchoscopy with broncho-
alveolar lavage (BAL) after segmental allergen challenge
(SAC). We detected an increase in pro-inflammatory cy-
tokines (IL-6) and immune modulating cytokines (IL-2,
IFN-γ and IL-10) along with an increase in lymphocytes
and the suppressor cells, regulatory T (Treg) and mye-
loid derived suppressor cells (MDSC). Although we did
not detect expression of CD30 on eosinophils, we did
detect significant membrane expression of CD30 on
Tregs and the presence of sCD30 in the BAL fluid of
adult atopic asthmatics.
Methods
Data collected from the Costimulation Inhibition in
Asthma (CIA) trial (ClinicalTrials.gov NCT00784459)
[10] was pooled and re-analyzed for this manuscript. For
detailed methods and a description of the participant
population and inclusion/exclusion criteria, please refer
to reference [10]. In brief, nonsmoking males and fe-
males between 18 and 50 years of age with previously di-
agnosed mild asthma by NAEPP guidelines were
identified. At screening, participants underwent skin
prick testing of cat allergen extract, short ragweed aller-
gen extract (Ambrosia artemisiifolia), and standardized
dust mite allergen extracts (Dermatophagoides farinae
and/or Dermatophagoides pteronyssinus) (all from Greer
Laboratories, Lenoir NC) to determine their reactivity
using standard methods [10-13] (Table 1). Eligible par-
ticipants underwent bronchoscopy with segmental aller-
gen challenge (SAC) with instillation of 5 ml allergen
solution at a concentration 1000X the minimum skin re-
active test dose, with a maximum of 1:100 dilution of
the stock allergen . Repeat bronchoscopy was performed
48 hours later with BAL performed in the same sub-
segment in which allergen had previously been instilled.
The study was approved by the Washington University
Institutional Review Board.
Measurement of BAL total cell counts and differentials
In the research laboratory, total cell counts were deter-
mined, cytospins prepared and manual differentials
performed immediately following bronchoscopy [10].
The BAL fluid was centrifuged and the supernatant
concentrated, using Ultracentrifugation Filter Units
(Millipore, Billerica MA), to approximately 1/20th of the
original volume, aliquoted and frozen at −80°C for fur-
ther analysis.
Flow cytometric analysis
The cell pellet recovered from the BAL was resuspended
in PBS containing 1% BSA and incubated with anti-
bodies directed against the following cell subsets: T cells
were identified as CD4 or CD8, as naïve (CD45RA) or
memory (CD45RO), and surface phenotyped for CD28,
CD25 or CD30. B cells were identified as CD19+. NK
cells were identified as CD56+. Regulatory T cells were
identified by staining with CD4, CD25 and FoxP3. Den-
dritic cells were identified via lineage cocktail negative
(CD3/CD14/CD16/CD19/CD20/CD56), HLA-DR high
and either CD123+ for plasmacytoid dendritic cells
(pDC), or CD11c+ for myeloid dendritic cells (mDC).
Myeloid derived suppressor cells (MDSC) were identi-
fied as lineage cocktail negative, CD33+ and HLA-DR
low. Eosinophils were identified by light scatter proper-
ties, CD16 negative and CD11b+. Fluorescently conju-
gated antibodies were purchased from BD Biosciences
(San Jose, CA), BioLegend (San Diego, CA) or
eBiosciences (San Diego, CA). In brief, 1-2x106 BAL
cells were labeled with fluorescently conjugated anti-
bodies at room temperature for 30 minutes. After label-
ing, RBC were lysed in 1X RBC lysis buffer (eBioscience)
for 1–2 minutes and extensively washed in FACS wash
(eBioscience). For FoxP3 staining, after surface labeling,
cells were labeled with anti-FoxP3 antibody according
to the manufactures protocol (human FoxP3 kit,
eBioscience). The labeled cells were then analyzed on a
4-color FACSCalibur flow cytometer using CellQuest soft-
ware (Becton-Dickinson Corporation, Mountainview,
CA). Samples were gated on a lymphocyte gate followed
by a second gate relevant for the population being ana-
lyzed (i.e., CD4+) and a minimum of 10,000 gated events
collected. Data was further analyzed using Winlist v7 soft-
ware (Verity Software Corporation, Topsham, ME).
Measurement of cytokine and soluble CD30 levels
BAL fluid was analyzed for cytokine content using the
Cytokine Bead Array (Th1/Th2/Th17 kit, BD Biosci-
ences) per the manufacturer’s instructions. The soluble
fragment of CD30 (sCD30) was measured by a standard
enzyme-linked immunosorbent assay (ELISA) per the
manufacturer’s directions (human sCD30 ELISA kit,
Table 1 Allergens used for titrated skin prick testing
1:100000 1:1000000 1:10000000 Total
Cat 2 3 5 10
Ragweed 4 5 2 11
D farinae 1 0 1 2
D Pteronyssinus 1 0 0 1
The dilution of allergen that provoked a positive test during titrated skin prick
testing is shown. Shown is the number of subjects that had a positive test at
the indicated dilution of allergen. 24 subjects were recruited for the initial trial
with pre-randomization data re-analyzed for this study. Adapted from Table E8
(reference [10]).
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Abnova, Walnut, CA). The limit of detection of the
CBA is 5 pg/mL while the sCD30 ELISA is 0.3 ng/mL.
Statistical analysis
All data were analyzed using either SAS version 9.3
(SAS Institute, Cary, NC) or Prism version 4 (GraphPad
Software Inc., La Jolla, CA). Outcomes are presented as
the mean ± standard deviation or graphically as indi-
vidual subject points. A non-parametric two-tailed
Mann–Whitney U test was performed between pre-
and post-SAC data. A 1-way ANOVA (Kruskal-Wallis)
and Dunn’s Multiple Comparison Test for individual
means was performed when analyzing groups of 3 or
more. A p-value <0.05 was considered significant.
Results
Inflammatory response to allergen
We re-analyzed data from 24 atopic asthmatics that
underwent a bronchoscopy and allergen challenge prior
to randomization in the parent trial [10]. As indicated in
Figure 1, allergen challenge led to an increase in the
total cell number present in the BAL fluid (1.5x105 ±
6.5x104 vs 8.8x105 ± 1.5x106; p < 0.001). There was also
a significant change in the cellular composition, with an
increase in both eosinophils (28.7% ± 26.2%) and neutro-
phils (4.5% ± 7.3%), along with a decrease in macro-
phages detected (−32.1% ± 26.0%) (Figure 1).
We measured the concentrations of pro-inflammatory
(IL-6 and TNF) and T cell-derived (IL-10, IL-2, IL-17,
IL-4 and IFN-γ) cytokines in the BAL by multi-plex
ELISA. IL-6, was significantly induced following allergen
challenge (30.8 ± 82.1 vs 311.6 ± 540.0 pg/mL, Figure 1B)
while TNF was only detected in a single subject (< 10
pg/mL, data not shown). The T cell-dependent cytokines
were not detected pre-allergen; however, IL-2 (4.2 ± 8.8
pg/mL), IFN-γ (6.0 ± 19.3 pg/mL) and IL-10 (5.9 ± 18.2
pg/mL) were detected in some of the subjects
(Figure 1B). Neither IL-4 nor IL-17A was observed post-
allergen challenge in BAL fluid (data not shown).
Surprisingly, most subjects had no detectable levels of T
cell-derived cytokines even after allergen instillation in
the lung (Figure 1B). An analysis based upon the type of
allergen instilled and/or the dilution of allergen that in-
duced a positive skin test did not yield statistically rele-
vant differences due to the limited number of subjects in
each group (Table 1). These data indicate that the instil-
lation of allergen in the lung induces the infiltration of
inflammatory cells and the production of both pro-
inflammatory and T-cell dependent cytokines.
Allergen challenge results in recruitment of innate and
adaptive immune cells to the lung
Multi-color flow cytometry was utilized to provide a
more detailed phenotypic analysis of immune cells re-
covered following allergen challenge. An increase in
CD4+ T cells along with a decrease in CD8+ T cells was
observed 48 hours following allergen challenge (Figure 2).
The innate immune response to allergen has also been
recognized as an important component of asthma [5];
therefore, we determined the recruitment of natural
killer cells (Nk) and dendritic cells (DC) to the lung. No
change in Nk or myeloid dendritic cells (mDC) was ob-
served; however, a small yet significant increase in
plasmacytoid dendritic cells (pDC; 0.5% ± 0.5% vs 3.9%
± 6.8%; p < 0.05) was observed in the BAL fluid after al-
lergen challenge (Figure 2).
To further characterize the inflammatory response in
the lung following allergen challenge, we enumerated
the number of suppressor cells present in the lung.
Regulatory T cells (Tregs) and myeloid derived suppres-
sor cells (MDSC) are important mechanisms for down-
modulating immune responses to antigen; interestingly,
both were recruited to the lung following allergen chal-
lenge (Tregs: 4.2% ± 2.1% vs 7.0% ± 4.4% [p < 0.001];
MDSCs: 10.4% ± 8.5% vs 20.6% ± 5.9% [p < 0.01])
(Figure 2). In addition to being present in the BAL, this
MDSC population expressed co-stimulatory B7-molecules
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Figure 1 Segmental allergen challenge (SAC) induces an inflammatory response detected in the BAL fluid of atopic asthmatics.
In A), total cell counts and differential analysis are presented for BAL fluid obtained pre- and post-SAC. In B), cytokine levels in the BAL fluid
were measured by multiplex ELISA using the Cytokine Bead Array (CBA). Shown is the re-analysis performed on the 24 subjects enrolled in the
randomized, placebo controlled, double blinded Costimulation Inhibition of Asthma (CIA) trial at pre-randomization. In A (right panel), the
average (change in percent cell type) is presented with error bars representing ± the standard deviation with an (* = p < 0.05; ** = p <0.01;
*** = p < 0.001). Each subject is represented by a single circle in the graphs with p values presented. Due to pre-SAC cytokines being below the
detection limit of the assay (5 pg/mL), no statistical analysis was performed for IL-10, IL-2 or IFN-γ.
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(CD80 12.2% ± 17.4% and CD86 25.7% ± 12.5%,
Additional file 1).
In addition to analyzing the percentage of lymphocyte
populations, we performed an extensive phenotypic ana-
lysis of these cell subsets. An increase in the percentage
of CD45RA+ (naïve or effector memory) T cells (1.1% ±
0.6% vs 5.6% ± 5.4%; p < 0.001) CD4+ and CD8+ (13.3%
± 8.7% vs 21.2% ± 13.5%; p < 0.01) T cells was observed
post-allergen challenge along with a reduction in mem-
ory (76.8% ± 12.4% vs 70.3% ± 14.8%; p < 0.05) CD8+ T
cells (Figure 3). We detected an increase in the percent-
age of cells that expressed the activation marker CD25
(IL-2R) for both CD4+ (16.0% ± 7.4% vs 19.8% ±
6.9%; p < 0.001) and CD8+ (0.7% ± 0.8% vs 1.3% ±
1.3%; p < 0.0001) T cells (Figure 3). These data dem-
onstrate that allergen challenge results in the recruit-
ment of activated CD4+ and CD8+ T cells and
innate immune cells along with specific regulatory
cell populations.
CD30 expression in BAL fluid after allergen challenge
CD30 has been shown to be expressed on eosinophils
[14,15], and is associated with Th2 type T lymphocytes
[16] and may correlate with severity of asthma [17,18];
therefore, we analyzed whether CD30 was expressed on
BAL cells and present in the BAL fluid after allergen
challenge. Contrary to some reports in the literature
[14,15], we were unable to detect any CD30 expression
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Figure 3 Expansion in both naïve and activated T cells in the BAL fluid after allergen challenge. T cell subsets in the BAL fluid pre- and
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on the surface of BAL eosinophils by multi-color flow
cytometry (Figure 4) or by immuno-histochemical stain-
ing of cytospins (data not shown) either pre- or post-
allergen challenge. However, CD30 expression was
detected on a low yet significant percentage of T and B
cells (Figure 4) and by immuno-histochemical staining
of BAL cytospins (data not shown) obtained following
allergen challenge. Of note, the percentage of CD30+
Tregs (22.1% ± 9.1%) was ~10-fold more than detected
on either B cells (2.1% ± 2.8%) or T cells (CD4+ 3.2% ±
2.0%; CD8+ 0.3% ± 0.7%) (Figure 4). Soluble CD30
(sCD30), the cleaved fragment of membrane CD30
[19,20], was quantitated by ELISA in the concentrated
BAL fluid. There was a 4-fold increase in sCD30 protein
in the BAL fluid upon allergen challenge (3.0 ± 1.1 vs
14.1 ± 24.6 in pg/mL; p < 0.05) (Figure 4). These data
identify the presence of CD30 positive lymphocytes, es-
pecially Tregs, but not eosinophils, and sCD30 in the
BAL fluid after allergen challenge of atopic asthmatics.
Discussion
In this study, we took advantage of results originally
obtained in an interventional trial designed to test the
effects of inhibition of T cell costimulation on the re-
sponse of mild atopic asthmatics to allergen challenge
[10]. Data obtained prior to administration of study drug
provided a comprehensive data set describing the in-
flammatory response to allergen. We found that allergen
instillation in the airway results in the recruitment of
both innate and adaptive immune cells to the lung, in-
cluding populations of suppressor cells. We also
detected elevated expression of CD30, predominantly on
regulatory T cells. Thus, the inflammatory response to
allergen is a complex mixture of cell types.
Clinical and animal studies have supported the role of
T lymphocytes as controllers of the aberrant Th2 initi-
ated response and eosinophils as predominant effectors
that induce asthma symptoms. The most dominant Th2
cytokine in asthma is IL-4 which has a plethora of activ-
ity including increasing IgE production, and differentiat-
ing T cells from a Th0 to Th2 [21,22]. We detected an
increase in eosinophil percentage yet no significant in-
crease in IL-4 after allergen challenge. Batra et al. deter-
mined the peak level of IL-4 is reached within 24 hours
after allergen challenge [23] potentially explaining the
lack of IL-4 detected in our study. In most subjects the
majority of cytokines were below the limits of detection.
This might reflect the extensive dilution that occurs due
to the BAL procedure. Given this limitation, a meaning-
ful biological difference is hard to conclude from these
data.
Asthma is a predominate Th2 disease but there is also
data for Th1 and Th17 responses. Th2 effector responses
in asthma such as eosinophil recruitment, mucus pro-
duction and AHR are inhibited by IFN-γ which is pro-
duced by Th1 T lymphocytes [1]. We detected a
significant increase in IFN-γ as well as neutrophils which
are recruited by IFN-γ [1] after allergen challenge
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(Figure 1A and 1B). Thus, our data supports a role for
both Th2 and IFN-γ responses in asthma.
Allergen challenge in asthmatics induces changes in
both innate and adaptive cellular populations. Although
we did not detect increases in B lymphocytes, a significant
increase in CD4+ T lymphocytes while a significant de-
crease in CD8+ T lymphocytes were observed (Figure 2).
Furthermore, we observed alterations in T lymphocyte
differentiation including: increases in naïve or effector
memory (CD45RA+) percentages, increased CD25 (IL-2R)
expression, and a decreased memory CD8+ pool after
allergen challenge signifying a T cell response to antigen
[1,24]. This is consistent with mouse models of asthma
where increased levels of IFN-γ inhibit the generation of
memory T cells [25] further contributing to the expansion
of an effector T cell pool [26].
We did not observe differences in Nk cells or myeloid
dendritic cells (mDC), innate cells important in asthma
pathology [5]; however, a significant increase in
plasmacytoid dendritic cells (pDC) was detected after al-
lergen challenge. The recruitment of pDC may be part
of the anti-inflammatory response in asthma [5,27]. In
accordance with this anti-inflammatory response, an in-
crease in regulatory T cells (Treg) as well as increased
IL-10 secretion, a regulatory T and pDC effector cyto-
kine, were detected after allergen challenge (Figures 2
and 1B). Regulatory T cells inhibit allergic responses by
1) suppressing myeloid dendritic cells (mDC) important
for T lymphocyte activation and differentiation, 2)
inhibiting Th1/Th2 and Th17 differentiation, 3)
inhibiting IgE production, 4) preventing T lymphocyte
migration into the lung and 5) inhibiting effector cell
function of mast cells, basophils and eosinophils [5]. Im-
portantly, we further identified an additional innate cell
population termed myeloid derived suppressor cells
(MDSC) as being increased after allergen challenge in
adult atopic asthmatics (Figure 2). Our report is the first
to identify MDSC in the BAL fluid of adult atopic asth-
matics after allergen challenge. Interestingly in a mouse
model of asthma, MDSC were shown to recruit regula-
tory T cells and down modulate T lymphocyte responses
[28]. We also show that MDSC expressed co-stimulatory
ligands, both CD80 and CD86, which have been associ-
ated with inducing Th2 T cells [3] as well as producing
IL-10 [29]. Therefore, multiple suppressor cell types are
associated with the anti-inflammatory response detected
in the lung after allergen challenge.
Soluble CD30 is increased in the serum of pediatric
asthma patients when compared to healthy individuals
[18,30] as well as after allergen challenge in our study.
We also detected sCD30 in the serum prior to allergen
challenge (20.3 ± 8.0 ng/mL; data not shown) in adult
atopic asthmatics. The role of soluble CD30 in asthma is
not clear but is thought to block CD30-CD153 induced
apoptosis and the induction of IgG class switching on B
cells [31]. The presence of sCD30 in the BAL after aller-
gen challenge may play a role in either preventing apop-
tosis of activated lymphocytes or in their differentiation.
However, the role of sCD30 in asthma is unknown and
requires further study.
Contrary to reports that detected mRNA and low sur-
face expression of CD30 on eosinophils [14,15], we did
not observe any CD30 expression on eosinophils by ei-
ther flow cytometry (Figure 4A) or immuno-
histochemistry (data not shown). We did however detect
membrane CD30 on lymphocytes, especially regulatory
T cells, after allergen challenge. CD30 expression on
CD4+ T cells has been associated with IL-4 secretion
[16] while CD30+ eosinophils undergo apoptosis in asth-
matics [14,15]. Memory CD8+ T lymphocytes express
CD30 [32], yet in our study the lowest percentage of
CD30+ cells were CD8+ T lymphocytes. This may be
partly explained by the decreased memory pool of CD8+
T cells after allergen challenge (Figure 3). There are no
reports of CD30 expression on regulatory T cells in
human asthma. In mouse model systems of allograft tol-
erance, a Th2 dominated response like asthma, CD30-
deficient Tregs failed to reject grafts [33,34]. Due to the
low cellularity of pre-allergen BAL sample, we were un-
able to measure CD30 expression on lymphocytes in
most subjects. However, in a single subject, the percent-
age of CD30+ Tregs in the BAL after allergen challenge
increased from 0.04% pre-allergen to 24.6% post-allergen
challenge (data not shown). The role of CD30 expression
on Tregs in asthma remains unclear; however, interaction
between CD30 on the Treg and CD153 on a CD8+ T cell
results in apoptosis of the CD8+ T cell [33,34]. Therefore,
we speculate that CD30+ regulatory T cells and sCD30
play a role in controlling asthma in a CD30-dependent
manner.
Conclusions
Atopic asthmatics increase innate and adaptive immune
cell populations after allergen challenge. In particular, al-
terations in both the activation and memory state of T
lymphocytes as well as detection of a novel suppressor
cell population termed MDSC. Furthermore, we
detected soluble CD30 and identified significant expres-
sion of CD30 on immune cells, most notably on regula-
tory T cells, not eosinophils in atopic asthmatics after
allergen challenge.
Additional file
Additional file 1: Expression of co-stimulatory ligands (B7) on
MDSC in the BAL fluid of atopic asthmatics. Myeloid derived
suppressor cells (MDSC) in the BAL fluid post-SAC were labeled with
specific fluorophore conjugated antibodies and analyzed by multi-color
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DR low and CD33+. The percent expression of co-stimulatory ligand
expression on MDSC was analyzed by gating on MDSC followed by
analysis of B7-1 (CD80) and B7-2 (CD86). Each subject is represented by a
single symbol on the graphs, with p values indicated.
Abbreviations
MDSC: Myeloid derived suppressor cells; BAL: Bronchoalveolar lavage;
sCD30: Soluble CD30; SAC: Segmental allergen challenge; Th2: T helper type
2; Th1: T helper type 1; mDC: Myeloid dendritic cell; pDC: Plasmacytoid
dendritic cell; Treg: Regulatory T cell; CIA: Costimulation inhibition of asthma
trial.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JSB developed and performed the research assays and contributed to the
formulation of the manuscript. ADP enrolled subjects, performed SAC
protocols, analyzed specimens and data. HYD CMP and SC performed
research assays and analyzed data. BMP was the lead research coordinator
and was involved in all aspects involving participants. NNJ was the lead
investigator at University of Wisconsin, MC and JMG collaboratively designed
the study as well as provided oversight over the conduct of the entire study.
All authors reviewed and contributed to the writing of the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
We thank Chandrika Christie for help with the research assays and Jamie
Tarsi for assistance in conducting this study. This study was funded by an
investigator initiated grant awarded to JMG by Bristol-Myers Squibb
Corporation and Medimmune Corporation.
Author details
1Department of Internal Medicine, Washington University School of
Medicine, St Louis, MO 63110, USA. 2Current affiliation: Department of
Internal Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
3Department of Internal Medicine, University of Wisconsin School of
Medicine and Public Health, Madison, WI 53792, USA.
Received: 25 July 2013 Accepted: 8 September 2013
Published: 17 September 2013
References
1. Cohn L, Elias JA, Chupp GL: Asthma: mechanisms of disease persistence
and progression. Annu Rev Immunol 2004, 22:789–815.
2. Umetsu DT, McIntire JJ, Akbari O, Macaubas C, DeKruyff RH: Asthma: an
epidemic of dysregulated immunity. Nat Immunol 2002, 3:715–720.
3. Ishmael FT: The inflammatory response in the pathogenesis of asthma.
J Am Osteopath Assoc 2011, 111:S11–S17.
4. Asquith KL, Ramshaw HS, Hansbro PM, Beagley KW, Lopez AF, Foster PS:
The IL-3/IL-5/GM-CSF common receptor plays a pivotal role in the
regulation of Th2 immunity and allergic airway inflammation. J Immunol
2008, 180:1199–1206.
5. Holgate ST: Innate and adaptive immune responses in asthma. Nat Med
2012, 18:673–683.
6. Deppong C, Degnan JM, Murphy TL, Murphy KM, Green JM: B and T
lymphocyte attenuator regulates T cell survival in the lung. J Immunol
2008, 181:2973–2979.
7. Deppong C, Juehne TI, Hurchla M, Friend LD, Shah DD, Rose CM, Bricker TL,
Shornick LP, Crouch EC, Murphy TL, et al: Cutting edge: B and T
lymphocyte attenuator and programmed death receptor-1 inhibitory
receptors are required for termination of acute allergic airway
inflammation. J Immunol 2006, 176:3909–3913.
8. Deppong CM, Parulekar A, Boomer JS, Bricker TL, Green JM: CTLA4-Ig
inhibits allergic airway inflammation by a novel CD28-independent,
nitric oxide synthase-dependent mechanism. Eur J Immunol 2010,
40:1985–1994.
9. Deppong CM, Xu J, Brody SL, Green JM: Airway epithelial cells suppress T
cell proliferation by an IFNgamma/STAT1/TGFbeta-dependent
mechanism. Am J Physiol Lung Cell Mol Physiol 2012, 302:L167–L173.
10. Parulekar AD, Boomer JS, Patterson BM, Yin-Declue H, Deppong CM, Wilson
BS, Jarjour NN, Castro M, Green JM: A randomized, controlled trial to
evaluate inhibition of T cell costimulation in allergen induced airway
inflammation. Am J Respir Crit Care Med 2013.
11. Weiland SK, Bjorksten B, Brunekreef B, Cookson WO, von Mutius E,
Strachan DP: Phase II of the International Study of Asthma and Allergies
in Childhood (ISAAC II): rationale and methods. Eur Respir J 2004,
24:406–412.
12. Romanet-Manent S, Charpin D, Magnan A, Lanteaume A, Vervloet D:
Allergic vs nonallergic asthma: what makes the difference? Allergy 2002,
57:607–613.
13. Pepys J, Roth A, Carroll KB: RAST, skin and nasal tests and the history in
grass pollen allergy. Clin Allergy 1975, 5:431–442.
14. Berro AI, Perry GA, Agrawal DK: Increased expression and activation of
CD30 induce apoptosis in human blood eosinophils. J Immunol 2004,
173:2174–2183.
15. Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H:
Extremely rapid and intense induction of apoptosis in human
eosinophils by anti-CD30 antibody treatment in vitro. J Immunol 2004,
172:2186–2193.
16. Rojas-Ramos E, Garfias Y, Jimenez-Martinez Mdel C, Martinez-Jimenez N,
Zenteno E, Gorocica P, Lascurain R: Increased expression of CD30 and
CD57 molecules on CD4(+) T cells from children with atopic asthma: a
preliminary report. Allergy Asthma Proc 2007, 28:659–666.
17. Lombardi V, Singh AK, Akbari O: The role of costimulatory molecules in
allergic disease and asthma. Int Arch Allergy Immunol 2010,
151:179–189.
18. Heshmat NM, El-Hadidi ES: Soluble CD30 serum levels in atopic dermatitis
and bronchial asthma and its relationship with disease severity in
pediatric age. Pediatr Allergy Immunol 2006, 17:297–303.
19. Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K,
Inoue J, Watanabe T: Tumor necrosis factor receptor-associated factor
(TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB
activation. J Biol Chem 1997, 272:2042–2045.
20. Ansieau S, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, Harada J,
Dougall B, Hubinger G, Kieff E, et al: Tumor necrosis factor receptor-
associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with
the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear
factor kappa B activation. Proc Natl Acad Sci U S A 1996,
93:14053–14058.
21. Barnes PJ: The cytokine network in asthma and chronic obstructive
pulmonary disease. J Clin Invest 2008, 118:3546–3556.
22. Maes T, Joos GF, Brusselle GG: Targeting interleukin-4 in asthma: lost in
translation? Am J Respir Cell Mol Biol 2012, 47:261–270.
23. Batra V, Musani AI, Hastie AT, Khurana S, Carpenter KA, Zangrilli JG, Peters
SP: Bronchoalveolar lavage fluid concentrations of transforming growth
factor (TGF)-beta1, TGF-beta2, interleukin (IL)-4 and IL-13 after
segmental allergen challenge and their effects on alpha-smooth muscle
actin and collagen III synthesis by primary human lung fibroblasts.
Clin Exp Allergy 2004, 34:437–444.
24. Wilson JW, Djukanovic R, Howarth PH, Holgate ST: Lymphocyte activation
in bronchoalveolar lavage and peripheral blood in atopic asthma. Am
Rev Respir Dis 1992, 145:958–960.
25. Wu CY, Kirman JR, Rotte MJ, Davey DF, Perfetto SP, Rhee EG, Freidag BL,
Hill BJ, Douek DC, Seder RA: Distinct lineages of T(H)1 cells have
differential capacities for memory cell generation in vivo. Nat Immunol
2002, 3:852–858.
26. Purwar R, Campbell J, Murphy G, Richards WG, Clark RA, Kupper TS:
Resident memory T cells (T(RM)) are abundant in human lung: diversity,
function, and antigen specificity. PLoS One 2011, 6:e16245.
27. Dua B, Watson RM, Gauvreau GM, O'Byrne PM: Myeloid and plasmacytoid
dendritic cells in induced sputum after allergen inhalation in subjects
with asthma. J Allergy Clin Immunol 2010, 126:133–139.
28. Deshane J, Zmijewski JW, Luther R, Gaggar A, Deshane R, Lai JF, Xu X,
Spell M, Estell K, Weaver CT, et al: Free radical-producing myeloid-derived
regulatory cells: potent activators and suppressors of lung inflammation
and airway hyperresponsiveness. Mucosal Immunol 2011,
4:503–518.
Boomer et al. Allergy, Asthma & Clinical Immunology 2013, 9:37 Page 7 of 8
http://www.aacijournal.com/content/9/1/37
29. Nakajima A, Watanabe N, Yoshino S, Yagita H, Okumura K, Azuma M:
Requirement of CD28-CD86 co-stimulation in the interaction between
antigen-primed T helper type 2 and B cells. Int Immunol 1997, 9:637–644.
30. Remes ST, Delezuch W, Pulkki K, Pekkanen J, Korppi M, Matinlauri IH:
Association of serum-soluble CD26 and CD30 levels with asthma, lung
function and bronchial hyper-responsiveness at school age. Acta Paediatr
2011, 100:e106–e111.
31. Hargreaves PG, Al-Shamkhani A: Soluble CD30 binds to CD153 with high
affinity and blocks transmembrane signaling by CD30. Eur J Immunol
2002, 32:163–173.
32. Ellis TM, Simms PE, Slivnick DJ, Jack HM, Fisher RI: CD30 is a signal-
transducing molecule that defines a subset of human activated CD45RO
+ T cells. J Immunol 1993, 151:2380–2389.
33. Dai Z, Li Q, Wang Y, Gao G, Diggs LS, Tellides G, Lakkis FG: CD4+CD25+
regulatory T cells suppress allograft rejection mediated by memory
CD8+ T cells via a CD30-dependent mechanism. J Clin Invest 2004,
113:310–317.
34. Zeiser R, Nguyen VH, Hou JZ, Beilhack A, Zambricki E, Buess M, Contag CH,
Negrin RS: Early CD30 signaling is critical for adoptively transferred
CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host
disease. Blood 2007, 109:2225–2233.
doi:10.1186/1710-1492-9-37
Cite this article as: Boomer et al.: A detailed phenotypic analysis of
immune cell populations in the bronchoalveolar lavage fluid of atopic
asthmatics after segmental allergen challenge. Allergy, Asthma & Clinical
Immunology 2013 9:37.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Boomer et al. Allergy, Asthma & Clinical Immunology 2013, 9:37 Page 8 of 8
http://www.aacijournal.com/content/9/1/37
